JPMorgan Chase & Co. 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-02 09:59 am Purchase |
2025-03-31 | 13G | Keros Therapeutics, Inc. KROS |
JPMORGAN CHASE & CO JPM |
2,587,146 6.300% |
2,587,146 (New Position) |
Filing |